8-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE

SECURITIES EXCHANGE ACT OF 1934

Date of report (Date of earliest event reported): June 24, 2009

ULURU Inc.

(Exact Name of Registrant as Specified in its Charter)

Nevada	000-49670	41-2118656
(State or Other Jurisdiction of Incorporation)	(Commission File Number)	(I.R.S. Employer Identification No.)

4452 Beltway Drive

Addison, Texas 75001

(Address of principal executive offices) (Zip Code)

Registrant’s telephone number, including area code: (214) 905-5145

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
o	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 7.01 Regulation FD Disclosure.

On June 24, 2009, ULURU Inc., a Nevada corporation (the “Company”), announced that at this time discussions to acquire York Pharma, plc, a public limited company incorporated under the laws of England and Wales (“York”), have been terminated.  The Company had previously announced that it intended to proceed with an offer to acquire all of the issued share capital of York, as described in that certain non-binding offer letter dated April 6, 2009 by and between the Company and York.  The Company delivered written notice of the termination of such discussions to York on June 19, 2009 (the “Notice”).  Also included in the Notice was notification to York that all amounts owing to the Company under that certain secured revolving credit facility established pursuant to that certain Note Purchase Agreement dated March 31, 2009 by and between the Company and York (the “Facility”), which amounts total US$1,000,000, plus all accrued but unpaid interest, are due and payable in accordance with the terms of the Facility.  This Facility is secured by substantially all of the assets of York and its subsidiaries.

A copy of a press release issued by the Company regarding the items described above is attached to this Current Report on Form 8-K as Exhibit 99.1 and is incorporated herein by reference.

Item 9.01	Financial Statements and Exhibits
(d)	Exhibits
Exhibit No.	Description
99.1	Press Release dated June 24, 2009.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	ULURU Inc.
Date: June 24, 2009	By:	/s/ Terrance K. Wallberg
		Terrance K. Wallberg
		Vice President and Chief Financial Officer

EXHIBIT INDEX

Exhibit No.	Description
99.1	Press Release dated June 24, 2009

EX-99.1

ULURU NEWS

Contact: Company

Renaat E. Van den Hooff

President & CEO

Terry K. Wallberg

Vice President & CFO

(214) 905-5145

 ULURU DISCUSSIONS

TO ACQUIRE YORK PHARMA, PLC ARE CURRENTLY TERMINATED

Addison, Texas, June 24, 2009; ULURU Inc. (NYSE AMEX: ULU) today announced that at this time discussions to acquire York Pharma, plc, a public limited company incorporated under the laws of England and Wales (“York”) have been terminated. Previously it had been announced that ULURU  intended to proceed with an offer to acquire all of the issued share capital of York, as described in the non-binding offer letter that ULURU and York signed on April 6, 2009.  ULURU has notified York that all amounts owing to ULURU under the secured revolving credit facility established pursuant to that certain Note Purchase Agreement dated March 31, 2009 by and between ULURU and York, which amounts total US$1,000,000, plus all accrued but unpaid interest, are due and payable in accordance with the terms of such facility. This revolving credit facility is secured by substantially all of the assets of York and its subsidiaries.

Despite this termination of discussions with York, ULURU remains committed to pursuing strategic opportunities and partnerships in the near future.

About ULURU Inc.:

ULURU Inc. is a specialty pharmaceutical company focused on the development of a portfolio of wound management and oral care products to provide patients and consumers with improved clinical outcomes through controlled delivery utilizing its innovative Nanoflex™ Aggregate technology and transmucosal delivery system. For more information about Altrazeal™, please visit www.Altrazeal™.com. For more information about ULURU Inc., please visit www.uluruinc.com.

This press release contains certain statements that are forward-looking within the meaning of Section 27a of the Securities Act of 1933, as amended, including statements relating to the possible acquisition of York by the Company and statements relating to potential strategic benefits of any such acquisition. These statements are subject to numerous risks and uncertainties, including but not limited to the risk factors detailed in the Company’s Annual Report on Form 10-K for the year ended December 31, 2008 and other reports filed by us with the Securities and Exchange Commission.